Gara Jalqabaatti › Saree Oljoo › Kansas

Qorannoo klinikaalii Saree Oljoo Kansas keessatti

Qorannoo 26 Saree Oljoo f Kansas keessatti hirmaatuu jiru.

Magaalota Kansas keessatti

Takkalaa qorannoo (Ingiliffa)

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

University of Kansas Cancer Center, Westwood
Cancer Center of Kansas, Wichita

Namoota walitti qabaa jiraSadarkaa 3

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT06982521

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Central Care Cancer Center - Garden City, Garden City
Central Care Cancer Center - Great Bend, Great Bend
Veteran Administration Eastern Kansas Healthcare, Leavenworth
fi 4 dabalataa

Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo

Umuriin 40 hanga 75 · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT05334069

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

The University of Kansas Cancer Center, Westwood

Namoota walitti qabaa jiraSadarkaa 3

Umuriin 60 fi ol · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT06377852

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Cancer Center of Kansas, Wichita

Namoota walitti qabaa jiraSadarkaa 3

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 15-Ful-2026 · NCT06492616

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

University of Kansas Hospital-Cancer Center, Fairway

Namoota walitti qabaa jiraSadarkaa 1/2

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 04-Ful-2026 · NCT07287917

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

AMR Kansas City Oncology, Kansas City

Namoota walitti qabaa jiraSadarkaa 3

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 02-Ful-2026 · NCT06072612

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Central Care Cancer Center - Garden City, Garden City
Central Care Cancer Center - Great Bend, Great Bend
HaysMed, Hays
fi 10 dabalataa

Namoota walitti qabaa jiraSadarkaa 3

Umuriin 18 hanga 60 · Dubartoota · Haaromfame 02-Ful-2026 · NCT05879926

Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry

Hays Medical Center Dreiling-Schmidt Cancer Institute, Hays
KCCC West, Kansas City
KCCC Overland Park, Overland Park
fi 3 dabalataa

Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo

Umuriin hundi · Saalaa hunda · Haaromfame 18-Hag-2026 · NCT02302742

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

University of Kansas Cancer Center, Kansas City
University of Kansas Cancer Center-Overland Park, Overland Park

Namoota walitti qabaa jiraSadarkaa 3

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 17-Hag-2026 · NCT06500481

Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC

University of Kansas Medical Center, Fairway

Namoota walitti qabaa jiraSadarkaa 2

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 12-Hag-2026 · NCT06263543

E-Mindfulness Approaches for Living After Breast Cancer

Cotton O'Neil Cancer Center / Stormont Vail Health, Topeka

Namoota walitti qabaa jiraSadarkaa 3

Umuriin 18 hanga 50 · Saalaa hunda · Haaromfame 04-Hag-2026 · NCT06748222

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

University of Kansas Medical Center (KUMC), Westwood

Namoota walitti qabaa jiraSadarkaa 1/2

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 04-Hag-2026 · NCT05579366

Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction

University of Kansas Cancer Center, Kansas City

Namoota walitti qabaa jiraSadarkaa 2Hojjettoota fayyaa simatamoo

Umuriin 45 hanga 74 · Dubartoota · Haaromfame 04-Hag-2026 · NCT06195306

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

University of Kansas Cancer Center, Kansas City

Namoota walitti qabaa jiraSadarkaa 2

Umuriin 18 hanga 55 · Dubartoota · Haaromfame 27-Ado-2026 · NCT06184750

HER2-positive Breast Cancer Registry

The University of Kansas Cancer Center, Westwood

Namoota walitti qabaa jiraQorannoo ilaalaa

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 17-Ado-2026 · NCT06603597

Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer

University of Kansas Cancer Center, Kansas City

Namoota walitti qabaa jiraSadarkaa 2

Umuriin 35 fi ol · Dubartoota · Haaromfame 07-Ado-2026 · NCT05941520

Integrated Cancer Repository for Cancer Research

Saint Luke's Cancer Instititute - South, Overland Park

Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo

Umuriin 19 hanga 110 · Saalaa hunda · Haaromfame 29-Wax-2026 · NCT02012699

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

The University of Kansas Cancer Center, Westwood

Namoota walitti qabaa jiraSadarkaa 3

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 18-Cam-2026 · NCT06757634

Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast Cancer

The University of Kansas Cancer Center (KUCC), Fairway
The University of Kansas Cancer Center - Westwood, Kansas City
KUCC - Indian Creek, Overland Park
fi 3 dabalataa

Namoota walitti qabaa jiraSadarkaa 2

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 06-Cam-2026 · NCT07220135

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

University of Kansas Cancer Center, Kansas City
The University of Kansas Cancer Center - Olathe, Olathe
University of Kansas Cancer Center-Overland Park, Overland Park
fi 8 dabalataa

Namoota walitti qabaa jiraSadarkaa 3

Umuriin 50 hanga 70 · Saalaa hunda · Haaromfame 23-Elb-2026 · NCT04852887

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

The University of Kansas Cancer Center, Westwood

Namoota walitti qabaa jiraSadarkaa 1/2

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 20-Elb-2026 · NCT06374459

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

HaysMed, Hays
Lawrence Memorial Hospital, Lawrence
The University of Kansas Cancer Center - Olathe, Olathe
fi 6 dabalataa

Namoota walitti qabaa jiraQorannoo ilaalaa

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 17-Bit-2026 · NCT06418204

EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)

University of Kansas Cancer Center, Westwood

Namoota walitti qabaa jiraQorannoo ilaalaa

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 20-Ama-2026 · NCT06401421

Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

Cancer Center of Kansas, Wichita

Namoota walitti qabaa jiraSadarkaa 2

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 10-Sad-2025 · NCT04553770

High Risk Breast Clinic: Protocol for Women at Increased Risk for Developing Breast Cancer

University of Kansas Medical Center, Kansas City

Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo

Umuriin 30 hanga 65 · Dubartoota · Haaromfame 29-Onk-2025 · NCT00291096

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

HaysMed University of Kansas Health System, Hays
University of Kansas Cancer Center-West, Kansas City
University of Kansas Cancer Center, Kansas City
fi 5 dabalataa

Namoota walitti qabaa jiraSadarkaa 3

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 08-Onk-2025 · NCT03418961

Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.